Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin?s lymphoma

AIDS

Volumn 24, Issue 15, 2010, Pages 2408-2412

  Cingolani, Antonella ^a   Torti, Lorenza ^b   Pinnetti, Carmela ^a   Donati, Katleen De Gaetano ^a   Murri, Rita ^a   Tacconelli, Evelina ^a   Larocca, Luigi Maria ^a   Teofili, Luciana ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b Institute of Hematology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; EFAVIRENZ; GRANULOCYTE COLONY STIMULATING FACTOR; INDINAVIR; LOPINAVIR; RALTEGRAVIR; RITONAVIR; VINBLASTINE; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUTROPENIA; NEUTROPHIL COUNT; PATIENT SAFETY; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; RITONAVIR; VINBLASTINE;

EID: 77957228859     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833db989     Document Type: Article

References (26)

1. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS associated non-Hodgkin's lymphoma. Lancet 1991; 337:805-809.
2. Bonnet F, Che'ne G. Evolving epidemiology of malignancies in HIV. Curr Opin Oncol 2008; 20:534-540.
3. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al., Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-736. (Pubitemid 351717418)
4. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J ClinOncol 2009; 27:884-890; Epub 2008Dec 29.
5. Navarro JT, Ribera JM, Oriol A, Vaquero M, Romeu J, Batlle M, et al. Influence of highly active antiretroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin lymphoma treated with cyclophosphamide, hydroxydoxorubicine, vincristine and prednisone. Br J Haematol 2001; 112:909-915. (Pubitemid 32322915)
6. Hoffmann C, Wolf E, Fätkenheuer G, Buhk T, Stoehr A, Plettenberg A, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS related lymphoma. AIDS 2003; 17:1521-1529. (Pubitemid 36900553)
7. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol 2008; 26:4834-4842; Epub 2008 June 30 [review].
8. Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani BN, Ratner L. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colonystimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multiinstitutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr 2000; 24:444-450.
9. Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 2008; 5:543-556; Review.
10. Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ, van Lunzen J, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol 2004; 125: 455-462. (Pubitemid 38916190)
11. Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, et al., GESIDA Group; GELCAB Group. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 2007; 92:191-198. (Pubitemid 46860198)
12. Kotb R, Vincent I, Dulioust A, Peretti D, Taburet AM, Delfraissy JF, Goujard C. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol 2006; 76:269-271.
13. Makinson A, Martelli N, Peyrière H, Turriere C, Le Moing V, Reynes J. Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease. Eur J Haematol 2007; 78:358-360. (Pubitemid 46365089)
14. Martin P, Leonard JP, Coleman M, Furman RR. Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis. Clin Lymphoma Myeloma 2009; 9:247-249.
15. DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1 December 2009.
16. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63:769-802. (Pubitemid 36432083)
17. Antoniou T, Tseng AL. Interactions between antiretroviral and antineoplastic drug therapy. Clin Pharmacokinet 2005; 44:111-145. (Pubitemid 40188937)
18. Spina M, Gabarre J, Rossi G, Fasan M, Schiantarelli C, Nigra E, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002; 100:1984-1988. (Pubitemid 35001227)
19. Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B, et al., German High-Grade Non Hodgkin's Lymphoma Study Group (DSHNHL). Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. Cancer 2006; 106:136-145. (Pubitemid 43032558)
20. Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio BC, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15:1483-1491. (Pubitemid 32744595)
21. Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10:145-155. (Pubitemid 40767640)
22. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, et al., BENCHMRK Study Teamsa. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010; 50:605-612.
23. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al., STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806; 2009.
24. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus integrase enzyme. Drug Metab Dispos 2007; 35:1657-1663. (Pubitemid 47296061)
25. Tricot L, Teicher E, Peytavin G, Zucman D, Conti F, Calmus Y, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9:1-7.
26. Fulco PP, Hynicka L, Rackley D. Raltegravir-based HAART regimen in a patient with large B-cell lymphoma. Ann Pharmacother 2010; 44:377-382.